Eva L. Feldman
Neurologist-scientist focused on ALS and diabetic neuropathy
Ann Arbor, Michigan
Summary
Leading physician-scientist in neurology who has advanced understanding of ALS and the neurologic complications of diabetes through sustained, high-impact translational research. umich+2
Translational innovator who has moved laboratory findings into first-in-kind clinical trials, notably leading FDA-authorized intraspinal neural progenitor cell transplantation studies for ALS. nih+1
Researcher focused on environmental and metabolic contributors to neurodegeneration, including development of an ALS environmental risk score linking persistent organic pollutants to ALS risk and survival. nih+1
Academic leader and mentor with institutional leadership roles, society presidencies, and recognition for training the next generation of clinicians and researchers. taubmaninstitute+2
Work
Education
Projects
Writing
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort
January 1, 2024Case-control study analyzing plasma levels of persistent organic pollutants (POPs) and showing associations between POP mixtures (environmental risk scores) and increased ALS risk and worse survival.
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
January 1, 2018Multi-author review describing mechanisms underlying diabetic neuropathy, emerging bioenergetics and axon–glia concepts, and implications for mechanism-based therapies.
Intraspinal Stem Cell Transplantation for Amyotrophic Lateral Sclerosis
January 1, 2016Review of preclinical rationale, translational strategy, and early clinical trials using spinal cord neural progenitor/stem cell transplantation as a therapy for ALS.